Premier Path Wealth Partners’s GSK GSK Stock Holding History

Premier Path Wealth Partners’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$589K	Sell	11,240 -3,543	-24%	-$187K	0.07%	241
2026 Q1	$816K	Sell	14,783 -8,293	-36%	-$449K	0.11%	187
2025 Q4	$1.13M	Sell	23,076 -7,578	-25%	-$353K	0.15%	137
2025 Q3	$1.32M	Sell	30,654 -884	-3%	-$34.5K	0.17%	127
2025 Q2	$1.21M	Sell	31,538 -2,173	-6%	-$83K	0.17%	143
2025 Q1	$1.31M	Sell	33,711 -563	-2%	-$20.6K	0.2%	124
2024 Q4	$1.16M	Buy	34,274 +5,967	+21%	+$215K	0.18%	139
2024 Q3	$1.16M	Buy	28,307 +1,239	+5%	+$50.7K	0.18%	144
2024 Q2	$1.04M	Buy	27,068 +1,148	+4%	+$48.3K	0.18%	143
2024 Q1	$1.11M	Buy	25,920 +3,869	+18%	+$160K	0.21%	128
2023 Q4	$828K	Buy	+22,051	New	+$792K	0.18%	141

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Premier Path Wealth Partners's GSK Position: Q2 2026 in Review

Premier Path Wealth Partners reduced its GSK (GSK) stake by 24% in Q2 2026, selling an estimated $187K and leaving 11,240 shares worth $589K. The position accounts for 0.07% of the portfolio, ranked #241.

Premier Path Wealth Partners first reported a position in GSK in Q4 2023 and has held it in 11 quarters since. The position peaked at $1.32M in Q3 2025. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Premier Path Wealth Partners held 11,240 shares of GSK worth $589K as of Q2 2026.
Premier Path Wealth Partners sold 3,543 GSK shares in Q2 2026, an estimated $187K.
GSK made up 0.07% of Premier Path Wealth Partners's portfolio in Q2 2026, its #241 holding.
Premier Path Wealth Partners first reported a position in GSK in Q4 2023 and has held it in 11 quarters since.
Premier Path Wealth Partners's GSK position peaked at $1.32M in Q3 2025.
1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Premier Path Wealth Partners's 13F filing for Q2 2026, filed 21 Jul 2026.